UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 11, 2009
Javelin Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-32949 | 88-0471759 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| 125 CambridgePark Drive, Cambridge Massachusetts | 02140 |
| (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code (617) 349-4500
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On August 11, 2009, Javelin Pharmaceuticals, Inc. issued a press release describing its initial review of top line results from a randomized, multicenter, double-blind, 1:1 placebo-controlled Phase 3 clinical study of Ereska™ (intranasal ketamine 30mg). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(d) Exhibits.
Exhibit No. | Description |
| | |
| 99.1 | Press Release of Javelin Pharmaceuticals, Inc. dated August 11, 2009 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | JAVELIN PHARMACEUTICALS, INC. | |
| | | | |
| | By: | /s/ Martin J. Driscoll | |
| | | Name: Martin J. Driscoll | |
| | | Title: Chief Executive Officer | |
| | | | |
Dated: August 11, 2009
EXHBIT INDEX
| Number | Document |
| | |
| 99.1 | Press Release of Javelin Pharmaceuticals, Inc. dated August 11, 2009 |
